NFE2L2 and prostate carcinoma: It was demonstrated that, in prostate cancer cells, apigenin inhibited growth by class I histone deacetylase alteration [78], and induced the demethylation of nuclear factor erythroid 2-related factor 2 (Nrf2) promoter, leading to the upregulation of Nrf2 mRNA [79].